MedTrace Logo

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

NCT01929408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 703

Last updated 2019-11-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Conditions

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • American Cancer Society, Inc.

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Mohamed Sorror, MD, MSc · Associate Member, Fred Hutch; Associate Professor of Medicine, UW

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-19
Primary Completion
2018-12-04
Completion
2018-12-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01929408 on ClinicalTrials.gov